久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國Satori  
阿爾茨海默病

Satori Pharmaceuticals is a developing life-changing therapeutics for Alzheimer's Disease (AD). The Company is led by a world class management team with deep CNS drug discovery and development experience that, combined, has helped develop over 100 clinical candidates and more than 10 approved drugs. The combined experience at Satori allows the management team to employ a top of industry approach to the development of its drug candidates – utilizing clinical strategies that are familiar to pharmaceutical companies working in AD.

The internal team is supported by a strong scientific advisory board made up of a growing list of the industry's leading experts on AD.

Satori is developing novel and proprietary small molecule compounds that are orally active and designed for chronic dosing in seniors. Their highly selective gamma secretase modulators reduce the production of amyloid beta 42, while sparing other gamma substrates. This selectivity and expected safety profile provide the opportunity for Satori's lead compounds to treat patients in early-stage disease, potentially slowing or stopping the disease, before major brain damage or onset of clinical symptoms.

Satori has raised $25M in equity capital from a syndicate of top-tier venture capital firms, including InterWest Partners, New Enterprise Associates, Prospect Venture Partners, and PureTech Ventures. These firms have track records of growing successful life sciences companies, and, collectively, have invested more than $12 billion over the life of their funds.

Given the novelty of Satori's chemical scaffold, we have filed strong composition of matter patent filings protecting our library of gamma secretase modulators.